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Summary
Background Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A 
receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the 
long-term effects of treatment with atrasentan on major renal outcomes.
Methods We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled 
adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25–75 mL/min per 1·73 m² 
of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300–5000 mg/g who had received maximum 
labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 
0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of 
at least 30% with no substantial fluid retention during the enrichment period (responders) were included in the 
double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily 
or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a 
composite of doubling of serum creatinine (sustained for ≥30 days) or end-stage kidney disease (eGFR 
<15 mL/min per 1·73 m² sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from 
kidney failure) in the intention-to-treat population of all responders. Safety was assessed in all patients who received 
at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number 
NCT01858532.
Findings Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, 
and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to 
the atrasentan group (n=1325) or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%) 
of 1325 patients in the atrasentan group and 105 (7·9%) of 1323 in the placebo group had a primary composite renal 
endpoint event (hazard ratio [HR] 0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, 
which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group 
than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%) of 1325 patients in the atrasentan 
group and 34 (2·6%) of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%) 
patients in the atrasentan group and 52 (3·9%) in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65).
Interpretation Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who 
were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor 
antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney 
disease.
Funding AbbVie.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Despite recommended treatment including renin–
angiotensin system inhibitors, people with type 2 
diabetes and chronic kidney disease remain at high risk 
of developing end-stage kidney disease and cardiovascular 
complications, particularly when high concentrations of 
albuminuria persist.1,2 Endothelin receptor antagonists 
reduce albuminuria and blood pressure, but can also 
cause sodium retention. A previous trial using high 
doses of avosentan, a non-selective endothelin receptor 
antagonist, in patients with diabetes and chronic kidney 
disease, was stopped prematurely because of an increased 
incidence of heart failure.3 By contrast, short-term 
treatment with low doses of the more selective endothelin 
A receptor antagonist atrasentan reduced albuminuria 
without causing significant fluid retention.4,5
The Study of Diabetic Nephropathy with Atrasentan 
(SONAR) was designed to assess the efficacy and 
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safety of atrasentan in patients with type 2 diabetes 
and chronic kidney disease. To enhance the potential 
benefit–risk profile of atrasentan, we selected re-
sponders to treatment, who were identified by the extent 
of reduction in albuminuria concentration during an 
initial open-label period of treatment with atrasentan. 
In this enrichment period, patients who developed 
evidence of fluid retention were excluded, in an attempt 
to minimise the risk of heart failure.6,7 The SONAR 
study therefore tested whether treatment of atrasentan 
would improve renal outcomes in carefully selected 
high-risk patients with diabetes and chronic kidney 
disease.
Methods
Study design
We did a double-blind, randomised, placebo-controlled 
event-driven trial at 689 sites in 41 countries. The trial 
protocol,6 which was approved by a central or local ethics 
committees at all study sites, and the statistical analysis 
plan are available in the appendix. The trial was designed 
and conducted in accordance with the Declaration of 
Helsinki (version amended October, 2000) and in 
compliance with the ethical principles of Good Clinical 
Practice.
Participants
Adults aged 18–85 years with type 2 diabetes and 
an estimated glomerular filtration rate (eGFR) of 
25–75 mL/min per 1·73 m² of body surface area, a urine 
albumin-to-creatinine ratio (UACR) of 300–5000 mg/g, 
serum albumin of at least 25 g/L, brain natriuretic peptide 
(BNP) concentration of no more than 200 pg/mL, serum 
potassium of at least 3·5 mmol/L, and systolic blood 
pressure of 110–180 mm Hg were eligible for partici-
pation. Treatment with a stable, recommended (or 
maximally tolerated) dose of an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker was 
required for at least 4 weeks before entry into the 
enrichment period. Key exclusion criteria were a 
diagnosis of or previous hospital admission for heart 
failure, a history of severe peripheral or facial oedema, 
diagnosis of type 1 diabetes, history of pulmonary 
hypertension, pulmonary fibrosis, or any lung diseases 
requiring oxygen therapy, and known non-diabetic kidney 
disease. Inclusion and exclusion criteria are in the 
appendix.
Randomisation and masking
Randomisation of patients to the atrasentan or placebo 
group (1:1) was done centrally through an interactive 
Research in context
Evidence before this study
We searched PubMed for all English-language publications 
published between Jan 1, 1990, and Feb 15, 2018, with the 
search terms ”endothelin-1”, “endothelin receptor antagonist”, 
”albuminuria”, ”kidney disease”, ”diabetes”, ”nephropathy”, and 
“randomised controlled trial”. Since the introduction of blood 
pressure control and renin–angiotensin–aldosterone blockade 
with an angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker, no additional therapy that lowers 
albuminuria has been shown to improve long-term renal 
outcomes. Endothelin receptor antagonists reduce albuminuria 
in experimental models of diabetes and in clinical studies of 
patients with chronic kidney disease with or without diabetes. 
A large randomised controlled trial in patients with type 2 
diabetes and chronic kidney disease using the fairly unselective 
endothelin receptor antagonist avosentan was terminated early 
because of an increased frequency of heart failure with 
avosentan. Atrasentan is a more selective endothelin receptor 
antagonist which, in short-term studies, reduced albuminuria 
with minimal sodium retention in patients with type 2 diabetes 
and chronic kidney disease. These preliminary findings justify 
conducting a phase 3 clinical trial to establish whether 
atrasentan can delay progression to end-stage kidney disease.
Added value of this study
We describe the results of a randomised, double-blind, 
placebo-controlled, phase 3 trial designed to study the efficacy 
and safety of the endothelin receptor antagonist atrasentan as 
an adjunct to angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker therapy for reducing the 
frequency of renal disease progression in patients with type 2 
diabetes and chronic kidney disease. To enhance the likelihood 
of detecting a treatment benefit while minimising the risk of 
heart failure, the trial used an enrichment design. Atrasentan 
responders were selected on the basis of the degree of 
albuminuria reduction during a 6-week atrasentan treatment 
period, while excluding patients who had fluid retention during 
this period to minimise the risk of heart failure. To our 
knowledge, this is the first clinical trial in patients with type 2 
diabetes to use an enrichment-responder design. During a 
median follow-up of 2·2 years, atrasentan reduced the rate of 
the primary renal endpoint compared with placebo (n=79 
[6·0%] vs 105 [7·9%]; hazard ratio [HR] 0·65; 95% CI 0·49–0·88; 
p=0·0047). Hospital admission for heart failure occurred in 
47 (3·5%) patients in the atrasentan group and 34 (2·6%) 
patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; 
p=0·208).
Implications of all the available evidence
Patients identified as showing substantial albuminuria 
reduction and minimal signs of sodium retention during 
short-term treatment with low-dose atrasentan had a 
significantly reduced risk of a renal event during long-term 
treatment with atrasentan compared with placebo. These data 
support a role for atrasentan in modifying renal risk in selected 
patients with type 2 diabetes and chronic kidney disease.
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voice response system using a computer-generated 
randomisation schedule and was stratified for geo-
graphic region, baseline UACR (≤1000 mg/g or 
>1000 mg/g), and UACR reduction achieved during the 
enrichment period (30% to <45%, 45% to <60%, and 
≥60%). Randomisation gating for enrolment into the 
non-responder cohort was implemented to ensure equal 
geographic and temporal distribution of non-responders 
and responders. Patients and all study personnel (except 
the independent data monitoring committee) were 
masked to treatment allocation and the study drug 
(atrasentan) and placebo were packaged identically with 
uniform capsule appearance, labelling, administration 
schedule, appearance, and odour.
Procedures
Following a screening and run-in period to optimise 
therapy with a diuretic and either an angiotensin-
converting enzyme inhibitor or an angiotensin receptor 
blocker, eligible patients entered a 6-week enrichment 
period, during which they received open-label treatment 
with atrasentan 0·75 mg once daily orally. The en richment 
period was used to identify atrasentan responders, defined 
as patients with at least a 30% reduction in UACR, who 
did not have substantial fluid retention (defined as an 
increase in bodyweight of 3 kg or more and a BNP increase 
to 300 pg/mL or more), and who did not have an increase 
in serum creatinine of more than 0·5 mg/dL and 20% 
from baseline. We intended to enrich the study population 
for patients who are likely to exhibit a renal benefit and 
unlikely to develop heart failure.
After 6 weeks, all responders who continued to meet 
eligibility criteria were randomly assigned to continue 
atrasentan 0·75 mg daily or switch to placebo. These 
responders comprised the primary analysis population 
used to establish the efficacy and safety of atrasentan. 
Additionally, a subset of non-responders (UACR 
reduction of <30% during the enrichment period and no 
evidence of significant fluid retention) were also 
randomly assigned to atrasentan or placebo to establish 
whether renal benefit was observed in this population.
After randomisation, in-person study visits were done 
after 1 month and 3 months and every 3 months 
thereafter. A follow-up visit was scheduled 45 days after 
the last dose of study drug to assess off-drug effects on 
clinical laboratory or physical parameters as well as 
adverse events. Participants were followed up to the point 
of withdrawal of consent or study closure.
During follow-up, study visits occurred every 3 months. 
At each follow-up visit, blood samples were taken for 
assessment of biochemical laboratory parameters and 
vital signs were recorded. Urine was collected at 
two separate visits 2 weeks apart at the beginning and 
end of the enrichment period, and at a single visit 
1 month and 12 months after randomisation, and then at 
yearly intervals for assessment of UACR. At specified 
visits, patients were instructed to collect three consecutive 
first-morning voids to establish the geometric mean 
UACR. Results were blinded during the run-in, enrich-
ment, and double-blind periods of the study to prevent 
unmasking. Study endpoints were recorded throughout 
follow-up when they occurred. The number of study 
visits depended on the duration of involvement in the 
study. Protocol-specific reasons for discontinuation of 
study medication included commencement of chronic 
dialysis, receipt of a kidney transplantation, or safety 
reasons.
Outcomes
The primary outcome was the efficacy of atrasentan in 
delaying the progression of chronic kidney disease, 
defined as the time from randomisation to the first 
occurrence of any of the following components of a 
composite endpoint: doubling of serum creatinine 
(confirmed by a second serum creatinine measurement 
≥30 days later), onset of end-stage kidney disease (defined 
as chronic dialysis for >90 days, kidney transplantation, 
eGFR <15 mL/min per 1·73 m² confirmed by a second 
measurement ≥90 days later, or death from kidney failure). 
Secondary endpoints were, in hierarchal order, time to at 
least a 50% eGFR reduction; a cardiorenal composite 
endpoint defined as doubling serum creatinine, end-stage 
kidney disease, cardiovascular death, non-fatal myocardial 
infarction, or non-fatal stroke; the primary composite 
renal endpoint in all randomly assigned patients (re-
sponders and non-responders combined); and a cardio-
vascular composite endpoint defined as cardiovascular 
death, non-fatal myocardial infarction, or non-fatal stroke. 
Time to hospital admission for heart failure in responders 
and time to the primary renal outcome in non-responders 
were additional prespecified outcomes. A masked inde-
pendent committee adjudicated the primary, secondary 
(except 50% eGFR reduction), and heart failure outcomes 
(appendix). We reported risk marker values over time to 
help understand the effects on clinical outcomes. Because 
endothelin receptor antag onists might cause sodium and 
fluid retention, adverse events of special interest included 
hypervolaemia, oedema, anaemia, and heart failure using 
prespecified standardised queries (appendix). Oedema 
was assessed at each study visit. Heart failure-related 
adverse events were collected on a specific case-report 
form.
Statistical analysis
The analytical approach and power calculation have 
been published previously,6 and the prespecified statis-
tical analysis plan is available with the protocol. We 
originally estimated that 425 events were needed to 
detect a 27% risk reduction (hazard ratio [HR] 0·73), 
with 90% power using a two-sided α level of 0·05, 
assuming an annual rate for the primary renal outcome 
of 6% in the placebo group. However, after all patients 
were randomly assigned, it became apparent that the 
rate of the primary composite outcome was much lower 
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than expected and that the time needed to accrue 
425 events would be much longer than expected. 
Accordingly, the sponsor decided in November, 2017, to 
stop the trial prematurely. The decision to stop the trial 
occurred before the planned interim analysis was done. 
Investigators were subsequently asked to perform the 
trial close-out procedures as described in the protocol.6,8 
At completion of the trial, 184 primary renal events had 
Figure 1: Trial profile
During the double-blind treatment period, 260 patients discontinued in the atrasentan group (111 adverse event, 37 withdrew consent, 14 were lost to 
follow-up, and 98 other) and 251 discontinued in the placebo group (94 adverse event, 58 withdrew consent, 21 lost to follow-up, and 78 other); some of 
these patients completed the study. *Reasons are not mutually exclusive. †Two patients who discontinued were later randomly assigned and included in the 
double-blind treatment period. ‡Adverse event, deterioration of the clinical status of the patient, investigator request, and other.
11 087 patients screened
5457 excluded*
5198 did not meet inclusion criteria
223 withdrew consent
45 lost to follow-up
112 other
1 unknown
5630 patients entered run-in
5117 patients entered enrichment
5107 started open-label atrasentan
2648 responders included in 
double-blind treatment period
1325 randomly assigned to the atrasentan group
1321 received at least one dose of assigned treatment
1144 completed study
1323 randomly assigned to the placebo group
1320 received at least one dose of assigned treatment
1131 completed study
513 excluded*
385 did not meet inclusion criteria
78 withdrew consent
11 lost to follow-up
81 other
1 unknown
10 did not start open-label atrasentan
1020 non-responders included in double-blind 
treatment period
4 did not start assigned treatment
1441 discontinued†
258 adverse effects
95 withdrew consent
13 lost to follow-up
796 non-responder randomisation closure
21 deterioration of patient’s medical status
26 investigator request
232 other reasons
177 did not complete study
69 withdrew consent 
17 lost to follow-up
91 other‡
3 did not start assigned treatment
192 did not complete study
93 withdrew consent 
26 lost to follow-up
73 other‡
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occurred providing more than 90% power to detect an 
HR of 0·62 and 80% power to detect an HR of 0·66 with 
a two-sided α level of 0·05 (appendix).
Primary efficacy and safety analyses were done in the 
responder population; the primary efficacy analysis 
included all patients, analysed by intention to treat and the 
safety analysis included all patients who received at least 
one dose of study drug during the double-blind treatment 
period. Cox proportional hazard regression was used to 
estimate the HR and the 95% CI for atrasentan compared 
with placebo for the primary, secondary, and heart failure 
outcomes. For patients who had more than one event 
during follow-up, survival time to the first relevant 
endpoint was used in each analysis. The treatment effect 
in the model was adjusted for log-transformed UACR 
values, serum albumin, age, and eGFR at ran dom isation. 
These covariates were pre specified on the basis of pre-
vious studies showing that they are strong predictors of 
renal outcomes in patients with type 2 diabetes and 
chronic kidney disease.9,10 The Cox proportional hazard 
assumptions were verified by visual inspection of the 
log(–log[survival]) curve and by adding a time-by-treatment 
interaction to the Cox model. These analyses showed no 
violations of the model assumptions. Treatment effects for 
the sec ondary and heart failure outcomes were analysed 
using a similar model. p values from the Cox model 
and from a stratified log-rank test, adjusting for the 
stratification factors at randomisation, are reported. If 
superiority of atrasentan over placebo was demonstrated 
for the primary endpoint at a two-sided significance level 
of 0·05, secondary endpoints were tested hierarchically 
using the same significance level in a prespecified order, 
until superiority over placebo could no longer be shown. 
The effect of atrasentan on the primary endpoint was 
analysed in prespecified subgroups using the same Cox 
model as described for the primary renal endpoint. The 
effects of atrasentan on continuous outcomes such as 
UACR and blood pressure were analysed using a mixed 
model with repeated measurements with an unstructured 
covariance matrix used to estimate within-subject corre-
lations, and a Satterthwaite method to estimate degrees of 
freedom. Change in eGFR per year was calculated by a 
random coefficient model with treatment as a fixed effect, 
and baseline eGFR, time, and interaction of treatment by 
time as linear covariates, with intercept and time as 
random effects. Analyses were done with SAS, version 9.4. 
An independent data safety monitoring committee 
oversaw the study (appendix). The study was registered at 
ClinicalTrials.gov (NCT01858532). 
Role of the funding source
The funder participated in study design, data collection, 
data analysis, data interpretation, and reviewing and 
approving the manuscript, but was not involved in the 
writing of the report. Employees of the funder reviewed 
the manuscript and gave suggestions for important 
intellectual content and approved the manuscript for 
Atrasentan (n=1325) Placebo (n=1323)
Characteristics
Age, years 64·9 (8·6) 64·7 (8·7)
Sex
Women 331 (25·0%) 352 (26·6%)
Men 994 (75·0%) 971 (73·3%)
Race
White 753 (56·8%) 744 (56·2%)
Black 73 (5·5%) 76 (5·7%)
Asian 446 (33·7%) 455 (34·4%)
Other 53 (4·0%) 48 (3·6%)
Weight, kg 84·6 (19·9) 84·6 (18·8)
Body-mass index, kg/m² 30·3 (5·8) 30·4 (5·5)
Duration of diabetes, years 16·8 (9·0) 16·7 (9·1)
Current smoker 205 (15·5%) 178 (13·5%)
Retinopathy 459 (34·6%) 453 (34·2%)
Blood pressure
Systolic, mm Hg 136·5 (15·2) 136·2 (14·8)
Diastolic, mm Hg 75·0 (9·9) 74·8 (10·0)
Serum creatinine, µmol/L 147·5 (43·2) 147·4 (40·9)
Estimated glomerular filtration rate, 
mL/min per 1·73 m²
44·0 (13·7) 43·7 (13·7)
Cholesterol, mmol/L
Total 4·6 (1·2) 4·6 (1·2)
Low-density lipoprotein 2·7 (1·0) 2·7 (1·0)
High-density lipoprotein 1·1 (0·4) 1·2 (0·4)
Glycated haemoglobin, % 7·8% (1·5) 7·8% (1·5)
Serum albumin, g/L 39·4 (3·5) 39·3 (3·4)
Haemoglobin, g/L 129·9 (16·9) 128·8 (16·9)
Brain natriuretic peptide, pg/mL 48·0 (26·0–87·0) 49·0 (25·6–89·0)
Serum potassium, mmol/L 4·5 (0·6) 4·5 (0·6)
Urinary albumin-to-creatinine ratio, mg/g 797 (462–1480) 805 (444–1451)
Previous medication
Angiotensin-converting enzyme inhibitor 474 (35·8%) 487 (36·8%)
Angiotensin receptor blocker 861 (65·0%) 850 (64·2%)
β blocker 556 (42·0%) 541 (40·9%)
Calcium channel blocker 800 (60·4%) 775 (58·6%)
Diuretic
Loop 595 (44·9%) 599 (45·3%)
Thiazide 409 (30·9%) 409 (30·9%)
Other* 127 (9·6%) 150 (11·3%)
Statin 965 (72·8%) 994 (75·1%)
Glucose-lowering therapies
Insulin 838 (63·2%) 820 (62·0%)
Metformin 508 (38·3%) 534 (40·4%)
Sulphonylurea derivatives 374 (28·2%) 381 (28·8%)
Dipeptidyl peptidase 4 inhibitor 250 (18·9%) 295 (22·3%)
Glucagon-like peptide-1 receptor agonist 52 (3·9%) 56 (4·2%)
Sodium-glucose cotransporter 2 inhibitor 12 (0·9%) 24 (1·8%)
Antithrombotic drug† 753 (56·8%) 776 (58·7%)
Data are n (%), mean (SD), or median (IQR). *Chlorthalidone, indapamide, mefruside, metolazone, tripamide, and 
xipamide. †Anticoagulants and antiplatelets.
Table 1: Baseline characteristics at start of the enrichment period
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submission. Employees of the funder did not have critical 
comments on the interpretation or conclusions. The 
corresponding author had full access to all the data in the 
study. All authors had final responsibility for the decision 
to submit the manuscript for publication.
Results
Between May 17, 2013, and July 13, 2017, 11 087 patients 
were screened, of whom 5457 were excluded because they 
did not meet exclusion criteria; 5630 entered the run-in 
period, of whom 513 were excluded; and 5117 entered the 
enrichment period (figure 1). 4711 patients completed the 
enrichment period, of whom 2648 were responders and 
were randomly assigned to atrasentan (n=1325) or placebo 
(n=1323). A selection of 1020 of the non-responders were 
randomly assigned to atrasentan (n=509) or placebo 
(n=511). Thus, not all non-responders were included in 
the double-blind treatment period. 
Responders who entered the double-blind treatment 
period were followed up for a median of 2·2 years 
(IQR 1·4–2·9). During follow-up, 260 (19·6%) of 
1325 patients in the atrasentan group and 251 (19·0%) 
of 1323 in the placebo group discontinued treatment 
prematurely. At the end of the study, vital status was 
unknown for 119 (9·0%) patients in the atrasentan 
group and 141 (10·7%) patients in the placebo group; 
1148 (86·6%) patients in the atrasentan group and 
1130 (85·4%) in the placebo group were followed up 
until a timepoint between completion of the study and 
study completion end date and 58 and 52 were known to 
have died before study completion.
Baseline characteristics, including medications for 
diabetes and kidney disease, were balanced between 
the groups (table 1). Mean age was 64·8 years 
(SD 8·7), 683 (25·8%) were women, mean eGFR was 
43·8 mL/min per 1·73 m² (SD 14), and median UACR 
was 803 mg/g (450–1469; table 1).
Among the 2648 responders, UACR decreased from 
baseline by 51·8% (95% CI 51·4–52·4) during the 
enrichment period. Systolic blood pressure decreased 
Figure 2: UACR, systolic blood pressure, BNP, and bodyweight during the study
Geometric mean UACR (A), mean systolic blood pressure (B), geometric mean BNP (C), and mean bodyweight (D). Error bars are 95% CIs. Vertical dotted lines denote the start of the randomised 
treatment period. Patients who discontinued medication are included in figures but their data collected after 6-week post-treatment follow-up visit are excluded. BNP=brain natriuretic peptide. 
UACR=urine albumin-to-creatinine ratio.
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by 6·1 mm Hg (5·6–6·7), BNP increased by 6·1% 
(3·5–8·7), and bodyweight increased by 0·5 kg (0·4–0·6; 
figure 2). These changes were similar between patients 
sub sequently randomly assigned to atrasentan and those 
assigned to placebo in the double-blind treatment phase.
After randomisation, during the double-blind treat-
ment period, UACR increased more in the placebo group 
than in the atrasentan group (difference 33·6% [95% CI 
29·1 to 38·2]; p<0·0001), and the mean between-group 
difference in change in systolic blood pressure from 
randomisation was –1·6 mm Hg (95% CI –2·5 to –0·7; 
p=0·00054). Conversely, the increase in BNP from 
randomisation was 10·5% (95% CI 5·1 to 15·4; p<0·0001) 
higher with atrasentan than with placebo, and the mean 
difference in bodyweight change was 0·2 kg (95% CI 
–0·1 to 0·5; p=0·12; figure 2).
The composite primary outcome occurred in 79 (6·0%) 
of 1325 patients in the atrasentan group compared with 
105 (7·9%) of 1323 patients in the placebo group (HR 0·65 
[95% CI 0·49–0·88]; p=0·0047; table 2, figure 3A). The 
HR was 0·61 (95% CI 0·43–0·87; p=0·0055; figure 3B) 
for doubling of serum creatinine and 0·73 (0·53–1·01; 
p=0·060; figure 3C) for end-stage kidney disease. The 
effects were broadly con sistent across a wide range of 
prespecified subgroups (appendix).
The HR for the first secondary endpoint of at least 
50% eGFR decline was 0·73 (95% CI 0·55 to 0·98; 
p=0·038; table 2). The HR for the cardiorenal composite 
outcome was 0·80 (0·64 to 0·999; p=0·049). There was 
no effect of atrasentan on the composite cardiovascular 
outcome (HR 0·88 [0·64 to 1·22]; p=0·448). The 
mean rate of change in eGFR during the trial was 
–2·4 mL/min per 1·73 m² per year (95% CI –2·7 to –2·1) 
in the atrasentan group compared with –3·1 mL/min 
per 1·73 m² (–3·4 to –2·8) in the placebo group 
(p=0·00049).
Baseline characteristics of the 1020 non-responders 
were balanced between the treatment groups (appendix). 
Compared with responders, non-responders were 
younger, and had a slightly higher baseline UACR, and 
lower eGFR. Among non-responders, the primary renal 
outcome occurred in 73 (14·3%) patients in the atrasentan 
group compared with 87 (17·0%) in the placebo group 
(HR 0·75 [95% CI, 0·55–1·03]; p=0·079; figure 4). 
The effect of atrasentan on the primary renal outcome 
was consistent in responders and non-responders 
(pinteraction=0·41). The incidence of secondary endpoints 
and rate of eGFR change did not differ between treatment 
groups in non-responders (appendix).
In the responder and non-responder groups combined 
(n=3668), the primary renal outcome occurred in 
152 (8·3%) of 1834 patients in the atrasentan group and 
192 (10·5%) of 1834 patients in the placebo group 
(HR 0·72 [95% CI 0·58–0·89]; p=0·0023; figure 4, table 2).
The most frequent adverse events that were more 
commonly reported in the atrasentan than placebo group 
were fluid retention and anaemia. Serious adverse events 
occurred more frequently in the atrasentan group 
(1042 events in 479 [36·3%] of 1321 patients), than in the 
placebo group (903 events in 430 [32·6%] of 1320 patients). 
Fluid retention and anaemia, which are adverse events 
of special interest because they have been previously 
Atrasentan (n=1325) Placebo (n=1323) Hazard ratio (95% CI) p value*
Number Annual rate Number Annual rate
Primary outcome
Composite renal outcome 79 (6·0%) 2·8% 105 (7·9%) 3·7% 0·65 (0·49–0·88) 0·0047
Doubling of serum creatinine 56 (4·2%) 2·0% 78 (5·9%) 2·7% 0·61 (0·43–0·87) 0·0055
End-stage kidney disease 67 (5·1%) 2·4% 81 (6·1%) 2·9% 0·73 (0·53–1·01) 0·060
Secondary outcomes†
50% eGFR reduction 84 (6·3%) 3·0% 99 (7·5%) 3·5% 0·73 (0·55–0·98) 0·038
Cardiorenal composite endpoint‡ 147 (11·1%) 5·2% 172 (13·0%) 6·1% 0·80 (0·64–0·10) 0·049
Cardiovascular death 31 (2·3%) 1·1% 28 (2·1%) 1·0% 1·10 (0·66–1·83) 0·720
Non-fatal myocardial infarction 36 (2·7%) 1·3% 33 (2·5%) 1·2% 1·11 (0·69–1·78) 0·675
Non-fatal stroke 8 (0·6%) 0·3% 27 (2·0%) 1·0% 0·29 (0·13–0·64) 0·0021
Primary outcome in all randomly 
assigned patients§
152 (8·3%) 3·8% 192 (10·5%) 4·8% 0·72 (0·58–0·89) 0·0023
Cardiovascular composite endpoint¶ 72 (5·4%) 2·5% 81 (6·1%) 2·9% 0·88 (0·64–1·22) 0·448
Other outcome
Hospital admission for heart failure 47 (3·5%) 1·7% 34 (2·6%) 1·2% 1·33 (0·85–2·07) 0·208
Data are n (%) unless otherwise specified. eGFR=estimated glomerular filtration rate. Annual rates are numbers of events over total person-years of follow-up. *Cox model 
for the primary and secondary efficacy outcomes; the log-rank p value was 0·029 for the primary outcome; 0·163 for the time to a 50% eGFR reduction; 0·011 for primary 
outcome in the total population; and 0·446 for cardiovascular composite endpoint. †Secondary outcomes are ranked according to prespecified hierarchy. ‡Comprises 
doubling of serum creatinine, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. §Primary renal outcome in combined 
responders and non-responders (n=1834 atrasentan and n=1834 placebo). ¶Comprises cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
Table 2: Effects of atrasentan on renal and cardiovascular outcomes
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reported to be attributable to endothelin receptor 
antagonists, were more frequent in the atrasentan group 
than in the placebo group (table 3). Adjudicated hospital 
admission for heart failure occurred in 47 (3·5%) of 1325 
patients in the atrasentan group compared with 34 (2·6%) 
of 1323 patients in the placebo group (HR 1·33 [95% CI 
0·85–2·07]; p=0·208). 58 (4·4%) patients in the 
atrasentan group and 52 (3·9%) in the placebo group 
died (HR 1·09 [95% CI 0·75–1·59]; p=0·65 [Cox model]).
Among non-responders, fluid retention and anaemia 
were also more frequent in the atrasentan group than the 
placebo group (appendix). As with responders, some 
adverse events of special interest, including fluid 
retention and anaemia, occurred more frequently with 
atrasentan than with placebo (appendix). Adjudicated 
hospital admission for heart failure occurred in 26 (5·1%) 
of 508 patients in the atrasentan group compared with 
17 (3·3%) of 510 patients in the placebo group (HR 1·54 
[95% CI 0·83–2·86]; p=0·175). 26 (5·1%) patients in the 
atrasentan group and 27 (5·3%) patients in the placebo 
group died (HR 0·97 [95% CI 0·56–1·67]; p=0·909). 
Combining the responder and non-responder groups 
in a post-hoc analysis, the HR for adjudicated hospital 
admission for heart failure was 1·39 (95% CI 0·97–1·99; 
p=0·072).
Discussion
In patients with type 2 diabetes and chronic kidney 
disease, selected on the basis of having at least a 
30% reduction in UACR and no clinical signs of sodium 
retention during short-term, low-dose treatment with 
atrasentan, subsequent long-term treatment with this 
endothelin receptor antagonist significantly reduced 
the risk of the primary composite renal outcome of 
doubling of serum creatinine or end-stage kidney disease 
compared with placebo.
Guidelines recommend use of an angiotensin receptor 
blocker or angiotensin-converting enzyme inhibitor as 
well as optimised blood pressure and glycaemic control to 
minimise renal risk in patients with type 2 diabetes and 
albuminuria. Increased expression of endothelin-1 has 
Figure 3: Effects of atrasentan on the primary composite renal outcome and 
its components in responders
Composite primary renal outcome (A), doubling of serum creatinine (B), 
and end-stage kidney disease (C) in the intention-to-treat population of 
responders. Calculated by Cox proportional hazard regression models.
Figure 4: Effects of atrasentan on the primary composite renal outcome in 
non-responders and all responders and non-responders combined
Non-responders (A) and combined responders and non-responders (B). Primary 
composite renal outcome comprised doubling of serum creatinine and end-stage 
kidney disease. Calculated by Cox proportional hazard regression models.
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also been implicated in progressive loss of renal function 
in patients with diabetic nephropathy.11 This increase 
in renal endothelin-1 is stimulated by multiple factors 
associated with diabetic kidney disease, including acid-
aemia, angiotensin-II, dyslipidaemia, hypoxia, growth 
factors, inflammatory cytokines, oxidative stress, insulin, 
and hyperglycaemia. In turn, endothelin-1 exerts multiple 
pathophysiological effects, including injury to the vas-
culature (enhanced vasoreactivity and procoagulation), 
podocytes (nephron shedding, cytoskeletal disruption, and 
proteinuria), tubulointerstitium (fibrosis), and mesan-
gium (proliferation and extracellular matrix accumulation) 
as well as promoting inflammatory cell infiltration.11 In 
experimental studies, endothelin receptor antagonists 
improved renal morphology and function and reduced 
albuminuria through multiple mechanisms, including 
attenuated damage to mesangial cells, podocytes, renal 
tubules, and the glycocalyx.12–15 In clinical studies, endo-
thelin receptor antagonists reduced albuminuria and 
blood pressure.5,16,17 We therefore did this large, inter-
national, long-term trial examining the effects of adding 
atrasentan to the standard of care on clinically meaningful 
renal endpoints. The findings from SONAR support the 
value of atrasentan in protecting kidney function in 
carefully selected patients with type 2 diabetes and chronic 
kidney disease who show an initial reduction in 
albuminuria with short-term endothelin receptor blockade.
SONAR is, to our knowledge, the first trial in patients 
with diabetes and chronic kidney disease to use a design 
intended to select patients most likely to benefit from 
treatment, in accord with the concept of personalised 
medicine.18 We selected patients with at least a 
30% reduction in UACR, because previous observational 
studies and meta-analyses of randomised controlled trials 
indicated that this population is at substantially lower 
risk of progression of renal disease than patients with 
smaller reductions in albuminuria, regardless of the type 
of intervention.10,19–21 The difference in UACR between 
placebo and atrasentan treatment during the double-
blind treatment period in our study was smaller than the 
difference observed during the enrichment period, 
because the post-randomisation UACR in the placebo 
group did not completely return to baseline values. The 
incomplete reversal of UACR reduction in the placebo 
group could reflect a legacy effect, although the complete 
reversal in the atrasentan treatment group during the 
6-week washout phase at the end of the trial makes this 
possibility seem unlikely.
Patients who were more likely to tolerate an endothelin 
receptor antagonist were also selected by excluding those 
showing clinical signs of sodium retention. Previous 
studies in individuals with chronic kidney disease and 
heart failure have shown that endothelin receptor 
antagonists can precipitate or worsen heart failure, leading 
to premature termination of at least one trial.3 By contrast, 
two previous short-term studies (8 weeks and 12 weeks 
duration) of atrasentan showed marked reduction in 
albuminuria even at low doses that did not cause clinically 
significant fluid retention.4,5 These short-term results are 
important because patients who developed fluid retention 
on higher doses of atrasentan did so within the first 
2–4 weeks of treatment. However, even with the pre-
cautionary approach taken in our study, including the use 
of diuretics, hospital admission for heart failure was 
higher with atrasentan (47 [3·6%] of 1321) than placebo 
(34 [2·6%] of 1320) in responders, indicating the necessity 
for continued vigilant monitoring of these adverse effects 
if treatment with endothelin receptor antagonists were to 
be used in clinical practice. Early termination of the trial 
and the low number of cardiovascular events precluded 
any definitive assess ment of further cardiovascular risk.
Although our trial design was not traditional, it mimics 
clinical practice in which physicians frequently dis-
continue therapy in patients who do not respond or 
tolerate the drug—eg, in the treatment of hypertension. 
We can only be confident about our findings in the 
responder population because the study was not powered 
to assess the effect of atrasentan in the non-responders (or 
the difference in effect between responders and non-
responders) and the effect of atrasentan in the non-
responder population was not statistically significant. 
Therefore, in a clinical setting, a strict interpretation of 
our results would hold that monitoring of UACR response 
after atrasentan initiation is required and atrasentan 
should be discontinued if patients do not show a good 
response or have side-effects. However, the consistent 
Atrasentan (n=1321) Placebo (n=1320) p value*
Any serious adverse event 479 (36·3%) 430 (32·6%) 0·049
Adverse events leading to discontinuation 137 (10·4%) 122 (9·2%) 0·360
Deaths 58 (4·4%) 52 (3·9%) 0·630
Treatment-emergent adverse events of interest
Hypervolaemia or fluid retention 483 (36·6%) 426 (32·3%) 0·022
Cardiac failure† 72 (5·5%) 51 (3·9%) 0·064
Anaemia 244 (18·5%) 136 (10·3%) <0·0001
Vasodilation 126 (9·5%) 118 (8·9%) 0·638
Cardiac toxicity 147 (11·1%) 130 (9·8%) 0·310
Serious adverse events (>1% in either group)
Acute kidney injury 32 (2·4%) 28 (2·1%) 0·696
Pneumonia 32 (2·4%) 22 (1·7%) 0·216
Congestive cardiac failure 23 (1·7%) 15 (1·1%) 0·252
Acute myocardial infarction 21 (1·6%) 21 (1·6%) 1·0
Coronary artery disease 18 (1·4%) 17 (1·3%) 1·0
Anaemia 16 (1·2%) 10 (0·8%) 0·325
Hypoglycaemia 14 (1·1%) 8 (0·6%) 0·284
Urinary tract infection 16 (1·2%) 7 (0·5%) 0·092
Cardiac failure 13 (1·0%) 8 (0·6%) 0·381
Cataract 16 (1·2%) 8 (0·6%) 0·150
Hyperkalaemia 13 (1·0%) 13 (1·0%) 1·0
Data are n (%). *Fisher‘s exact test. †Cardiac failure events included all investigator-reported treatment-emergent 
adverse events.
Table 3: Adverse events during double-blind treatment period
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effect of atrasentan in the combined analysis of responders 
and non-responders suggests that this type of therapy 
might have a broader indication. Moreover, the explanation 
for any potential benefit in non-responders is unknown 
and requires further study, along with a proper assessment 
of the usefulness of the enrichment design. It is pos-
sible that responders are insufficiently separated from 
non-responders because of random fluctuations in 
albuminuria, but it is also possible that atrasentan slows 
renal disease progression through pathways unrelated 
to albuminuria change.22,23 Finally, the threshold of 
30% UACR reduction to define responders was arbitrary 
and might not be the optimal threshold to distinguish 
atrasentan responders from non-responders in terms of 
clinical outcomes.
The trial has limitations, the most important of which 
is its early termination because of a lower-than-planned 
event rate. The reason for the low event rate is unknown 
and requires further analysis. Nevertheless, the large 
treatment effect size observed and an adequate number 
of endpoints provided sufficient power to draw robust 
conclusions about the primary renal outcome. Further, 
vital status of some patients lost to follow-up remained 
unknown despite the trial close-out procedures being 
performed according to the protocol.6 Although these 
patients were similarly distributed across the placebo 
and atrasentan groups, this potential bias has to be taken 
into account in the trial interpretation. Additionally, 
during the trial, 19% of patients discontinued their 
assigned treatment. Although this proportion is similar 
to other trials in patients with diabetes and chronic 
kidney disease,24,25 this might have affected the benefit–
risk estimation.
In summary, SONAR showed that patients with 
type 2 diabetes and chronic kidney disease who were 
selected for a substantial UACR reduction and minimal 
clinical signs of sodium retention during short-term 
treatment with atrasentan had a significantly lower risk 
of doubling of serum creatinine or end-stage kidney 
disease during long-term treatment with this endothelin 
receptor antagonist compared with placebo. Data from 
this study and other trials with endothelin receptor 
antagonists could define the position of this class in 
the future treatment armamentarium of the diabetes 
population with high renal and cardiovascular risk.
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